Gabapentin Capsule
Product Images NDC 50090-1072

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-1072). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Equation Of Cockcroft And Gault (Gabapentin Fig1)

An illustration showing the formula for calculating creatinine clearance (CLCr), involving age, weight, serum creatinine, and a factor for female patients.*

FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)

A line graph comparing mean pain scores over an 8-week period between placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, while the y-axis shows mean pain scores from 0 to 10. The graph features a 4-week dose titration period followed by a 4-week fixed dose period, illustrating a decrease in pain scores for Gabapentin compared to placebo.*

FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig3)

A line graph showing mean pain score over a 7-week period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks including a 3-week dose titration period and a 4-week fixed dose period. The y-axis represents mean pain score ranging from 0 to 10.*

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)

Bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) groups. Two studies are shown: Study 1 with PBO at 12% and GBP 3600 at 29%; Study 2 with PBO at 14%, GBP 1800 at 32%, and GBP 2400 at 34%, with statistical significance indicated for gabapentin groups.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

A scatter plot chart showing percentage difference (%) on the y-axis against daily dose (mg) on the x-axis for Gabapentin studies labeled as STUDY a, STUDY b, and STUDY c. Data points are marked with distinct symbols for each study at doses 600, 900, 1200, and 1800 mg, illustrating a dose-response relationship.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure of gabapentin showing a cyclohexane ring bonded to an amino group (CH2NH2) and a carboxymethyl group (CH2CO2H).*

FDA Label Image

Label Image (Lbl500901072)

Gabapentin 400 mg capsules label from A-S Medication Solutions. The label lists storage instructions at 68-77 degrees Fahrenheit and indicates the package contains 90 capsules. It includes a lot number, product number, and a barcode with a QR code directing to dosage and safety information.*

FDA Label Image

Label Image (Lbl500901597)

Label of Gabapentin 100 mg capsules by A-S Medication Solutions. The label shows the product name Gabapentin 100 mg, with packaging information for 30 capsules. Storage instructions indicate to store at 68 to 77 degrees Fahrenheit. The label includes the NDC 50090-1597-0 and the labeler address in Southside, Georgia.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.